Bristol-Myers Squibb Announces US Investments and Closures

BMS changes its US geographic footprint with R&D investments and closures.
Dec 14, 2016
By Pharmaceutical Technology Editors

Bristol-Myers Squibb announced on December 13, 2016 that it was strengthening the company’s R&D capabilities in the United States and integrating biologics development with clinical manufacturing. The plans include a new R&D building at the company’s Lawrenceville, NJ campus, construction at its New Brunswick, NJ facility, and an expansion of its Devens, MA campus. The company also plans to close its Hopewell, NJ site by mid-2020 and will not renew its Seattle, Lake Union Steam Plant site in 2019. Previously announced plans to close BMS’ Wallingford, CT site were confirmed.

“These important changes to our US geographic footprint will ensure we have the structural, operational, and financial flexibility to deliver as effectively as possible on our mission for patients,” said Giovanni Caforio, MD, chief executive officer, Bristol-Myers Squibb, in a press release. “Today’s announcement underscores our commitment to make the right investments to continue to deliver on the promise of our pipeline and to bring transformational medicines to patients, today and in the future.”

Source: Bristol-Myers Squibb

native1_300x100
lorem ipsum